|
Sipavibart
Sipavibart, sold under the brand name Kavigale, is a medication used for the prevention of COVID-19 in people who are immunocompromised.[1] Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunization against SARS-CoV-2 by binding its spike protein receptor binding domain.[1][3] Sipavibart was approved for medical use in the European Union in January 2025.[1][2] Medical usesSipavibart is indicated for the pre-exposure prophylaxis of COVID-19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) and who are immunocompromised due to a medical condition or receipt of immunosuppressive treatments.[1][2] Society and cultureLegal statusIn December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kavigale, intended for the prevention of COVID-19 in immunocompromised people aged twelve years of age and older.[1] Kavigale was reviewed under the EMA's accelerated assessment program.[1] The applicant for this medicinal product is AstraZeneca AB.[1] Sipavibart was approved for medical use in the European Union in January 2025.[1][2] NamesSipavibart is the international nonproprietary name.[4] Sipavibart is sold under the brand name Kavigale.[1][2] References
Further reading
Information related to Sipavibart |
||||||||||||||||||||||||||||||
.svg){kind=small}
